Illumina, Inc. vs Utilities Select Sector SPDR Fund — how do they compare? Illumina, Inc. trades at $269.18 (market cap $39.95B), while Utilities Select Sector SPDR Fund trades at $41.28 (market cap $23.60B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| ILMN | XLU | |
|---|---|---|
Market Cap | $39.95B | $23.60B |
Volume | 3,169,503 | 28,758,237 |
Sector | Health | — |
52-Week High | $293.69 | $47.73 |
52-Week Low | $91.00 | $39.25 |
Typical Hold Time | 83 Days | 80 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
XLU trades at $41.09, down 0.15% with mixed technical signals showing a bullish moving average trend but neutral oscillators. The ETF recently hit 52-week lows amid sector-wide pressure from rising interest rates. Support levels cluster around $40-41 while resistance sits at $41-42. Recent news highlights utility stocks as oversold with potential defensive appeal during market volatility.
The outlook remains cautious given interest rate sensitivity, though current levels may offer value for defensive positioning. Key risks include further rate hikes and AI power demand uncertainty. Analyst sentiment is divided with technical indicators suggesting near-term consolidation potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →